At present, anti-her-2 therapy and anti-HR + therapy have significantly improved the prognosis of HER-2 overexpression and HR + breast cancer, while triple-negative breast cancer (TNBC) lacks therapeutic targets. Here, HR is linked to triple-negative breast carcinoma.